News
Public · Published
Canaccord Genuity maintains Beam Therapeutics at Buy, lowers price target to $78 from $79
Canaccord Genuity kept its Buy rating on Beam Therapeutics but lowered its price target to $78 from $79. The revised target is 1.3% lower and implies 180.7% upside from the November 4 closing price of $27.79. Recent analyst targets ranged from $30 to $80.
Published:
Updated:
What happened
Canaccord Genuity kept its Buy rating on Beam Therapeutics but lowered its price target to $78 from $79. The revised target is 1.3% lower and implies 180.7% upside from the November 4 closing price of $27.79. Recent analyst targets ranged from $30 to $80.
Confirmed
Global impact / market context
The lower target signals a small reduction in Canaccord’s stated valuation, but its Buy rating was unchanged. If investors use analyst targets to guide expectations, this revision could modestly temper optimism; the article gives no company operating update or explanation for the change.
Analyst inference
Recent analyst targets cited in the article span $30 to $80, showing differing views among firms. Canaccord’s $78 target sits near the top of that range, while the $27.79 reference close is the basis for its stated upside calculation.
Confirmed
What to watch
- Check whether Canaccord explains the target cut or changes its rating later; the article provides no reason for the revision or any change to its Buy view. Analyst inference
- Compare future analyst targets with the cited $30–$80 range to see whether views are converging or diverging; no later recommendations are reported here. Analyst inference
- Look for company updates on research progress, spending, or funding, which could affect costs and cash available; none are included in this article. Analyst inference
Evidence
- Original source link unavailable